FRALAN GATTE: Open Payments
NPI 1912990516 · LAKE CHARLES, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$136 in 8 payments from 7 companies in 2025. Trend: 2023 $3,608 · 2024 $195 · 2025 $136
Food & beverage: $136
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
| Alkermes, Inc. | 1 | $15 |
| Neurocrine BioSciences, Inc. | 1 | $15 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: UZEDY, ABILIFY MAINTENA, CAPLYTA, INVEGA SUSTENNA, ARISTADA, INGREZZA, COBENFY, ABILIFY ASIMTUFII.
Industry payments across LA — which companies pay providers there.
